Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain
Pharmacology Biochemistry and Behavior · 2024
DOI: 10.1016/j.pbb.2024.173883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Biochemistry and Behavior, 2024. Verfasst von Elise M Weerts und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Behavioral Biology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA. Hauptthemen laut MEDLINE: Rats, Sprague-Dawley, Inflammation, Anxiety, Cannabinoids. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Cannabigerol (CBG) is a phytocannabinoid found in cannabis that is promoted for medical use and other health benefits, but current empirical data on the behavioral effects of CBG are lacking. The purpose of this study was to evaluate the effects of a wide dose range of orally administered CBG on outcomes related to its potential cannabimimetic effects (cannabinoid tetrad), as well as effects on anxiety-like behavior, inflammation and related pain hypersensitivity. In a series of experiments, male and female Sprague Dawley rats received oral CBG (per os [p.o.]) or vehicle prior to testing of effects on 1) the cannabinoid tetrad (30-600 mg/kg, p.o.): assessments of locomotor activity, body temperature, antinociception (tail flick test), and catalepsy (bar test); 2) acoustic startle response (ASR) test of anxiety-like behavior (30-300 mg/kg, p.o.); 3) carrageenan-induced inflammation (paw edema), hyperalgesia (Hargreaves test), and allodynia (von Frey test) tests (10-60 mg/kg, p.o.). Positive control groups were administered THC (0-30 mg/kg, p.o.) for the cannabinoid tetrad assay, the benzodiazepine lorazepam (0-3 mg/kg, intraperitoneal [i.p.]) for the ASR test, or the opioid analgesic morphine (0-10 mg/kg, i.p.) for the carrageenan-induced inflammation and pain hypersensitivity tests. CBG did not produce cannabimimetic actions in the tetrad, but increased locomotor activity at the highest doses (300-600 mg/kg). THC produced typical dose-related cannabimimetic effects. CBG did not produce anxiolytic effects in the ASR test, while groups pretreated with lorazepam showed reductions in ASR. Finally, pretreatment with CBG prior to an intraplantar injection of carrageenan did not prevent the induction of an acute inflammatory state (i.e., increased paw edema and associated hyperalgesia and allodynia). In contrast, morphine alleviated hyperalgesia and allodynia induced by intraplantar carrageenan but did not affect the development of paw edema. In sum, these data do not support the use of oral CBG for anxiety or inflammatory pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Behavioral Biology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA.
- Division of Behavioral Biology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA. Electronic address: cfmoore@jhmi.edu.
Zitieren
APA
Weerts, E. M., Jenkins, B. W., Kuang, R. Y., Hausker, A., & Moore, C. F. (2024). Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2024.173883
Vancouver
Weerts EM, Jenkins BW, Kuang RY, Hausker A, Moore CF. Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain. Pharmacology Biochemistry and Behavior. 2024. doi:10.1016/j.pbb.2024.173883
BibTeX
@article{Weerts2024,
author = {Weerts, Elise M and Jenkins, Bryan W and Kuang, Robbie Y and Hausker, Alma and Moore, Catherine F},
title = {Orally administered Cannabigerol (CBG) in rats: Cannabimimetic actions, anxiety-like behavior, and inflammation-induced pain},
journal = {Pharmacology Biochemistry and Behavior},
year = {2024},
doi = {10.1016/j.pbb.2024.173883}
}
EUVIMED